SCHEMBL23970525

SCHEMBL23970525

CC(C)(C)OC(=O)c1cnc(C(F)(F)F)nc1CCCCCO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.38
NR1H2 P55055 5/20 0.38
NR1H3 Q13133 3/20 0.38
JUN P05412 5/20 0.36
NFKB1 P19838 5/20 0.36
NFKB2 Q00653 5/20 0.36
RELA Q04206 5/20 0.36
FOS P01100 4/20 0.36
HSP90AA1 P07900 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PDE4B Q07343 3/20 0.33
TKT P29401 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PDE4A P27815 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE11A Q9HCR9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23970518 0.75 TDP1 (0.39) RXRANR1H2NR1H3TDP1ALDH1A1
SCHEMBL30159250 0.75 TDP1 (0.39) RXRANR1H2NR1H3TDP1ALDH1A1
SCHEMBL23971334 0.75 TDP1 (0.37) RXRANR1H2NR1H3TDP1KMT2A
SCHEMBL23970627 0.74 TDP1 (0.38) RXRANR1H2NR1H3TDP1KMT2A
SCHEMBL30850136 0.74 TDP1 (0.38) RXRANR1H2NR1H3TDP1KMT2A
SCHEMBL23970516 0.71 TDP1 (0.38) RXRANR1H2NR1H3TDP1ALDH1A1
SCHEMBL23971080 0.70 TDP1 (0.39) NR1H2TDP1ALDH1A1KDM4ESSTR4
SCHEMBL30410313 0.70 TDP1 (0.39) NR1H2TDP1ALDH1A1KDM4ESSTR4
SCHEMBL23971276 0.70 TDP1 (0.39) NR1H2TDP1ALDH1A1KDM4ESSTR4
SCHEMBL23970756 0.70 TDP1 (0.36) RXRANR1H2NR1H3TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
EP-4143189-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-03-08 EP disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 CN disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 RXRA 3649/4885NR1H2 2698/4885NR1H3 2309/4885
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 RXRA 3649/4885NR1H2 2698/4885NR1H3 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.